Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
08:05am, Tuesday, 13'th Jul 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after mark
This Explosive Biotech Is Taking On a Huge New Market
11:17am, Wednesday, 30'th Jun 2021
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
08:05am, Tuesday, 22'nd Jun 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Please replace the release dated May 19, 2021 with the following corrected version due to a change in the fourth paragraph. The updated release reads: GUARDANT H
Guardant Health: A Stalwart With 20% Upside
04:23am, Monday, 07'th Jun 2021
Investing in a company operating in an industry tailwind usually leads to significant profits.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021,
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx test as the first and only liqui
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
01:52am, Friday, 28'th May 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, a
Where Guardant Health Stands With Analysts
10:50am, Tuesday, 25'th May 2021
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1 Somewhat Bullish 1 1 0 2 Indifferent
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?
06:11am, Saturday, 22'nd May 2021
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as the first
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
05:56pm, Wednesday, 19'th May 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), to present data demonstrating the use of the company's proprietary blood tests to advance precision oncology, including cance
3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming
06:16am, Thursday, 13'th May 2021
Falling costs are ushering in a new era of screening for a dreaded disease.
This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic
10:15am, Friday, 07'th May 2021
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2021 Results - Earnings Call Transcript
10:24pm, Thursday, 06'th May 2021
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2021 Results - Earnings Call Transcript
